{"transactions":[{"id":4623512,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Warrant (right to buy)","published_at":"2026-09-21T20:57:09.000Z","date":"2026-09-21","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The warrant vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025."}],"balance_after":79996,"derivative":{"exercise_price":7.8,"expiration_date":"2034-07-14","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000907654-26-000100","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1333277/000090765426000100/form4.xml","form_type":"4"}},{"id":4623511,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-09-21T20:57:09.000Z","date":"2026-09-21","kind":"sale","planned":true,"acquired":false,"shares":2667,"price":95.3115,"value":254195.7705,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.05 to $95.75, inclusive."}],"balance_after":29995,"source":{"system":"sec-edgar","filing":"0000907654-26-000100","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1333277/000090765426000100/form4.xml","form_type":"4"}},{"id":4623510,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-09-21T20:57:09.000Z","date":"2026-09-21","kind":"sale","planned":true,"acquired":false,"shares":601,"price":94.4426,"value":56760.0026,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.02 to $94.98, inclusive."}],"balance_after":32662,"source":{"system":"sec-edgar","filing":"0000907654-26-000100","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1333277/000090765426000100/form4.xml","form_type":"4"}},{"id":4623509,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-09-21T20:57:09.000Z","date":"2026-09-21","kind":"sale","planned":true,"acquired":false,"shares":3832,"price":93.3173,"value":357591.8936,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.89 to $93.80, inclusive."}],"balance_after":33263,"source":{"system":"sec-edgar","filing":"0000907654-26-000100","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1333277/000090765426000100/form4.xml","form_type":"4"}},{"id":4623508,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-09-21T20:57:09.000Z","date":"2026-09-21","kind":"sale","planned":true,"acquired":false,"shares":2900,"price":92.3689,"value":267869.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.87 to $92.78, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4."}],"balance_after":37095,"source":{"system":"sec-edgar","filing":"0000907654-26-000100","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1333277/000090765426000100/form4.xml","form_type":"4"}},{"id":4623507,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-09-21T20:57:09.000Z","date":"2026-09-21","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":7.8,"value":78000.0,"ownership":{"direct":true},"balance_after":39995,"source":{"system":"sec-edgar","filing":"0000907654-26-000100","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1333277/000090765426000100/form4.xml","form_type":"4"}},{"id":4618685,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-09-15T23:14:19.000Z","date":"2026-09-15","kind":"sale","planned":false,"acquired":false,"shares":1039,"price":95.71,"value":99442.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units."}],"balance_after":29995,"source":{"system":"sec-edgar","filing":"0000907654-26-000095","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1333277/000090765426000095/form4.xml","form_type":"4"}},{"id":687401,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-14T21:52:30.000Z","date":"2026-08-14","kind":"exercise","planned":true,"acquired":false,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The option vests as to 1/48 of the underlying shares monthly from January 1, 2025."}],"balance_after":120500,"derivative":{"exercise_price":12.5,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0000907654-26-000077","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000077/form4.xml","form_type":"4"}},{"id":687400,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Warrant (right to buy)","published_at":"2026-08-14T21:52:30.000Z","date":"2026-08-14","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The warrant vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025."}],"balance_after":89996,"derivative":{"exercise_price":7.8,"expiration_date":"2034-07-14","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000907654-26-000077","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000077/form4.xml","form_type":"4"}},{"id":687399,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-14T21:52:30.000Z","date":"2026-08-14","kind":"sale","planned":true,"acquired":false,"shares":3847,"price":111.1378,"value":427547.1166,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.66 to $111.22, inclusive."}],"balance_after":31034,"source":{"system":"sec-edgar","filing":"0000907654-26-000077","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000077/form4.xml","form_type":"4"}},{"id":687398,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-14T21:52:30.000Z","date":"2026-08-14","kind":"sale","planned":true,"acquired":false,"shares":9193,"price":110.0039,"value":1011265.8527,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.58 to $110.55, inclusive."}],"balance_after":34881,"source":{"system":"sec-edgar","filing":"0000907654-26-000077","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000077/form4.xml","form_type":"4"}},{"id":687397,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-14T21:52:30.000Z","date":"2026-08-14","kind":"sale","planned":true,"acquired":false,"shares":10200,"price":109.1131,"value":1112953.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.56 to $109.51, inclusive."}],"balance_after":44074,"source":{"system":"sec-edgar","filing":"0000907654-26-000077","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000077/form4.xml","form_type":"4"}},{"id":687396,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-14T21:52:30.000Z","date":"2026-08-14","kind":"sale","planned":true,"acquired":false,"shares":14696,"price":107.9735,"value":1586778.556,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.54 to $108.52, inclusive."}],"balance_after":54274,"source":{"system":"sec-edgar","filing":"0000907654-26-000077","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000077/form4.xml","form_type":"4"}},{"id":687395,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-14T21:52:30.000Z","date":"2026-08-14","kind":"sale","planned":true,"acquired":false,"shares":10434,"price":107.1402,"value":1117900.8468,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.54 to $107.53, inclusive."}],"balance_after":68970,"source":{"system":"sec-edgar","filing":"0000907654-26-000077","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000077/form4.xml","form_type":"4"}},{"id":687394,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-14T21:52:30.000Z","date":"2026-08-14","kind":"sale","planned":true,"acquired":false,"shares":3630,"price":106.0504,"value":384962.952,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.53 to $106.51, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4."}],"balance_after":79404,"source":{"system":"sec-edgar","filing":"0000907654-26-000077","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000077/form4.xml","form_type":"4"}},{"id":687393,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-14T21:52:30.000Z","date":"2026-08-14","kind":"exercise","planned":true,"acquired":true,"shares":42000,"price":12.5,"value":525000.0,"ownership":{"direct":true},"balance_after":83034,"source":{"system":"sec-edgar","filing":"0000907654-26-000077","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000077/form4.xml","form_type":"4"}},{"id":687392,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-14T21:52:30.000Z","date":"2026-08-14","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":7.8,"value":78000.0,"ownership":{"direct":true},"balance_after":41034,"source":{"system":"sec-edgar","filing":"0000907654-26-000077","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000077/form4.xml","form_type":"4"}},{"id":738556,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-06-15T22:50:21.000Z","date":"2026-06-15","kind":"sale","planned":false,"acquired":false,"shares":733,"price":69.69,"value":51082.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units."}],"balance_after":31034,"source":{"system":"sec-edgar","filing":"0000907654-26-000060","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000060/form4.xml","form_type":"4"}},{"id":839723,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-03-17T20:04:49.000Z","date":"2026-03-16","kind":"sale","planned":false,"acquired":false,"shares":733,"price":41.3,"value":30272.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units."}],"balance_after":31767,"source":{"system":"sec-edgar","filing":"0000907654-26-000029","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000029/form4.xml","form_type":"4"}},{"id":932708,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-23T22:36:46.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 1/48 of the underlying shares monthly from January 1, 2026."}],"balance_after":130000,"derivative":{"exercise_price":34.39,"expiration_date":"2036-01-22","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0000907654-26-000014","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000014/form4.xml","form_type":"4"}},{"id":932707,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-01-23T22:36:46.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":true,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or if not a trading day, the immediately preceding trading day)."}],"balance_after":32500,"source":{"system":"sec-edgar","filing":"0000907654-26-000014","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000014/form4.xml","form_type":"4"}},{"id":1295912,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-24T21:42:51.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":162500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/48 of the underlying shares monthly from January 1, 2025."}],"balance_after":162500,"derivative":{"exercise_price":12.5,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":162500},"source":{"system":"sec-edgar","filing":"0001062993-25-001087","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000106299325001087/form4.xml","form_type":"4"}},{"id":1563844,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:59:26.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":105625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":22.85,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":105625},"source":{"system":"sec-edgar","filing":"0000950170-24-035453","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035453/ownership.xml","form_type":"4"}},{"id":1563843,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:59:26.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":215000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":7.8,"expiration_date":"2033-01-24","underlying":"Common Stock","underlying_shares":215000},"source":{"system":"sec-edgar","filing":"0000950170-24-035453","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035453/ownership.xml","form_type":"4"}},{"id":1563842,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:59:26.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":107000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":2.94,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":107000},"source":{"system":"sec-edgar","filing":"0000950170-24-035453","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035453/ownership.xml","form_type":"4"}},{"id":1563841,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:59:26.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22167,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":5.78,"expiration_date":"2031-01-25","underlying":"Common Stock","underlying_shares":22167},"source":{"system":"sec-edgar","filing":"0000950170-24-035453","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035453/ownership.xml","form_type":"4"}},{"id":1563840,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:59:26.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":233176,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":7.89,"expiration_date":"2030-10-11","underlying":"Common Stock","underlying_shares":233176},"source":{"system":"sec-edgar","filing":"0000950170-24-035453","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035453/ownership.xml","form_type":"4"}},{"id":1563839,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-03-22T16:59:26.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28438,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay restricted stock unit award was cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of CymaBay common stock subject to such restricted stock unit award and (ii) $32.50, less applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-035453","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035453/ownership.xml","form_type":"4"}},{"id":1563838,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-03-22T16:59:26.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":41824,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the \"Merger Agreement\"), by and among CymaBay Therapeutics, Inc. (\"CymaBay\"), Gilead Sciences, Inc., a Delaware corporation (\"Gilead\"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead (\"Purchaser\"), among other things, Purchaser merged with and into the Company (the \"Merger\").  Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-035453","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035453/ownership.xml","form_type":"4"}},{"id":1575133,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-15T16:02:17.000Z","date":"2024-03-13","kind":"exercise","planned":false,"acquired":false,"shares":41824,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option grant vests as to 1/4 of the underlying shares on October 12, 2021 and as to 1/48 of the underlying shares monthly thereafter."}],"balance_after":8872,"derivative":{"exercise_price":7.89,"expiration_date":"2030-10-11","underlying":"Common Stock","underlying_shares":41824},"source":{"system":"sec-edgar","filing":"0001062993-24-006510","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324006510/form4.xml","form_type":"4"}},{"id":1575132,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-03-15T16:02:17.000Z","date":"2024-03-13","kind":"exercise","planned":false,"acquired":true,"shares":41824,"price":7.89,"value":329991.36,"ownership":{"direct":true},"balance_after":70262,"source":{"system":"sec-edgar","filing":"0001062993-24-006510","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324006510/form4.xml","form_type":"4"}},{"id":1669906,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-26T18:28:47.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":105625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2024."}],"balance_after":105625,"derivative":{"exercise_price":22.85,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":105625},"source":{"system":"sec-edgar","filing":"0001062993-24-001429","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324001429/form4.xml","form_type":"4"}},{"id":1669905,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-01-26T18:28:47.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":28438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The grant shall vest as to 1/4 of the shares on each of January 15, 2025, January 15, 2026, January 15, 2027 and January 15, 2028."}],"balance_after":28438,"source":{"system":"sec-edgar","filing":"0001062993-24-001429","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324001429/form4.xml","form_type":"4"}},{"id":1679278,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-16T19:07:09.000Z","date":"2024-01-16","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022."}],"balance_after":107000,"derivative":{"exercise_price":2.94,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001062993-24-000923","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324000923/form4.xml","form_type":"4"}},{"id":1679277,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-01-16T19:07:09.000Z","date":"2024-01-16","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":23.5796,"value":117898.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.48 to $23.70, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001062993-24-000923","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324000923/form4.xml","form_type":"4"}},{"id":1679276,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-01-16T19:07:09.000Z","date":"2024-01-16","kind":"exercise","planned":false,"acquired":true,"shares":5000,"price":2.94,"value":14700.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001062993-24-000923","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324000923/form4.xml","form_type":"4"}},{"id":1709734,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-12-15T16:35:37.000Z","date":"2023-12-15","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022."}],"balance_after":112000,"derivative":{"exercise_price":2.94,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001062993-23-022636","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323022636/form4.xml","form_type":"4"}},{"id":1709733,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-12-15T16:35:37.000Z","date":"2023-12-15","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":21.9805,"value":109902.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.66 to $22.33, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001062993-23-022636","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323022636/form4.xml","form_type":"4"}},{"id":1709732,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-12-15T16:35:37.000Z","date":"2023-12-15","kind":"exercise","planned":false,"acquired":true,"shares":5000,"price":2.94,"value":14700.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001062993-23-022636","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323022636/form4.xml","form_type":"4"}},{"id":1737370,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-11-17T17:57:10.000Z","date":"2023-11-15","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022."}],"balance_after":117000,"derivative":{"exercise_price":2.94,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001062993-23-021137","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323021137/form4.xml","form_type":"4"}},{"id":1737369,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-11-17T17:57:10.000Z","date":"2023-11-15","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":17.3778,"value":86889.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.55, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001062993-23-021137","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323021137/form4.xml","form_type":"4"}},{"id":1737368,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-11-17T17:57:10.000Z","date":"2023-11-15","kind":"exercise","planned":false,"acquired":true,"shares":5000,"price":2.94,"value":14700.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001062993-23-021137","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323021137/form4.xml","form_type":"4"}},{"id":1758361,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-10-18T18:21:37.000Z","date":"2023-10-16","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022."}],"balance_after":122000,"derivative":{"exercise_price":2.94,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001062993-23-019547","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323019547/form4.xml","form_type":"4"}},{"id":1758360,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-10-18T18:21:37.000Z","date":"2023-10-16","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":13.7596,"value":68798.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.65 to $13.89, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001062993-23-019547","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323019547/form4.xml","form_type":"4"}},{"id":1758359,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-10-18T18:21:37.000Z","date":"2023-10-16","kind":"exercise","planned":false,"acquired":true,"shares":5000,"price":2.94,"value":14700.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001062993-23-019547","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323019547/form4.xml","form_type":"4"}},{"id":1777894,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-19T17:23:45.000Z","date":"2023-09-15","kind":"exercise","planned":false,"acquired":false,"shares":53000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022."}],"balance_after":127000,"derivative":{"exercise_price":2.94,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":53000},"source":{"system":"sec-edgar","filing":"0001062993-23-018278","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323018278/form4.xml","form_type":"4"}},{"id":1777893,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-09-19T17:23:45.000Z","date":"2023-09-15","kind":"sale","planned":false,"acquired":false,"shares":24000,"price":16.8715,"value":404916.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023."},{"field":"shares","element":"transactionShares","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.44 to $17.09, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001062993-23-018278","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323018278/form4.xml","form_type":"4"}},{"id":1777892,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-09-19T17:23:45.000Z","date":"2023-09-15","kind":"exercise","planned":false,"acquired":true,"shares":24000,"price":2.94,"value":70560.0,"ownership":{"direct":true},"balance_after":24000,"source":{"system":"sec-edgar","filing":"0001062993-23-018278","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323018278/form4.xml","form_type":"4"}},{"id":1777891,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-09-19T17:23:45.000Z","date":"2023-09-15","kind":"sale","planned":false,"acquired":false,"shares":24000,"price":16.8707,"value":404896.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023."},{"field":"shares","element":"transactionShares","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.44 to $17.09, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001062993-23-018278","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323018278/form4.xml","form_type":"4"}},{"id":1777890,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-09-19T17:23:45.000Z","date":"2023-09-15","kind":"exercise","planned":false,"acquired":true,"shares":24000,"price":2.94,"value":70560.0,"ownership":{"direct":true},"balance_after":24000,"source":{"system":"sec-edgar","filing":"0001062993-23-018278","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323018278/form4.xml","form_type":"4"}},{"id":1777889,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-09-19T17:23:45.000Z","date":"2023-09-15","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":16.8656,"value":84328.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.49 to $17.05, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001062993-23-018278","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323018278/form4.xml","form_type":"4"}},{"id":1777888,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-09-19T17:23:45.000Z","date":"2023-09-15","kind":"exercise","planned":false,"acquired":true,"shares":5000,"price":2.94,"value":14700.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001062993-23-018278","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323018278/form4.xml","form_type":"4"}},{"id":1806296,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-08-16T16:57:19.000Z","date":"2023-08-15","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022."}],"balance_after":180000,"derivative":{"exercise_price":2.94,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001062993-23-016606","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323016606/form4.xml","form_type":"4"}},{"id":1806295,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-08-16T16:57:19.000Z","date":"2023-08-15","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":11.9101,"value":59550.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.64 to $12.21, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001062993-23-016606","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323016606/form4.xml","form_type":"4"}},{"id":1806294,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-08-16T16:57:19.000Z","date":"2023-08-15","kind":"exercise","planned":false,"acquired":true,"shares":5000,"price":2.94,"value":14700.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001062993-23-016606","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323016606/form4.xml","form_type":"4"}},{"id":1829762,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-07-14T18:52:36.000Z","date":"2023-07-14","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022."}],"balance_after":185000,"derivative":{"exercise_price":2.94,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001062993-23-014924","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323014924/form4.xml","form_type":"4"}},{"id":1829761,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-07-14T18:52:36.000Z","date":"2023-07-14","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":11.81,"value":59050.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001062993-23-014924","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323014924/form4.xml","form_type":"4"}},{"id":1829760,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-07-14T18:52:36.000Z","date":"2023-07-14","kind":"exercise","planned":false,"acquired":true,"shares":5000,"price":2.94,"value":14700.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001062993-23-014924","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323014924/form4.xml","form_type":"4"}},{"id":1841322,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-06-30T16:51:25.000Z","date":"2023-06-30","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022."}],"balance_after":190000,"derivative":{"exercise_price":2.94,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001062993-23-014259","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323014259/form4.xml","form_type":"4"}},{"id":1841321,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-06-30T16:51:25.000Z","date":"2023-06-30","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":10.05,"value":50250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001062993-23-014259","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323014259/form4.xml","form_type":"4"}},{"id":1841320,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-06-30T16:51:25.000Z","date":"2023-06-30","kind":"exercise","planned":false,"acquired":true,"shares":5000,"price":2.94,"value":14700.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001062993-23-014259","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323014259/form4.xml","form_type":"4"}},{"id":1889761,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-05-17T19:11:15.000Z","date":"2023-05-15","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022."}],"balance_after":195000,"derivative":{"exercise_price":2.94,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001062993-23-011430","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323011430/form4.xml","form_type":"4"}},{"id":1889760,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-05-17T19:11:15.000Z","date":"2023-05-15","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":10.3662,"value":51831.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.20 to $10.525, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001062993-23-011430","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323011430/form4.xml","form_type":"4"}},{"id":1889759,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-05-17T19:11:15.000Z","date":"2023-05-15","kind":"exercise","planned":false,"acquired":true,"shares":5000,"price":2.94,"value":14700.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001062993-23-011430","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323011430/form4.xml","form_type":"4"}},{"id":2043961,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-01-27T16:23:59.000Z","date":"2023-01-25","kind":"grant","acquired":true,"shares":215000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/48 of the underlying shares monthly from January 1, 2023."}],"balance_after":215000,"derivative":{"exercise_price":7.8,"expiration_date":"2033-01-24","underlying":"Common Stock","underlying_shares":215000},"source":{"system":"sec-edgar","filing":"0001062993-23-001488","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323001488/form4.xml","form_type":"4"}},{"id":2424293,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-01-27T16:59:42.000Z","date":"2022-01-25","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/48 of the underlying shares monthly from January 1, 2022."}],"balance_after":200000,"derivative":{"exercise_price":2.94,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001062993-22-001705","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299322001705/form4.xml","form_type":"4"}},{"id":2892493,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-01-28T14:48:38.000Z","date":"2021-01-26","kind":"grant","acquired":true,"shares":22167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/4 of the underlying shares on January 1, 2022, and vests as to 1/48 of the underlying shares monthly thereafter."}],"balance_after":22167,"derivative":{"exercise_price":5.78,"expiration_date":"2031-01-25","underlying":"Common Stock","underlying_shares":22167},"source":{"system":"sec-edgar","filing":"0001333277-21-000019","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000133327721000019/edgar.xml","form_type":"4"}},{"id":3007478,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-10-14T13:22:10.000Z","date":"2020-10-12","kind":"grant","acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/4 of the underlying shares on October 12, 2021, and vests as to 1/48 of the underlying shares monthly thereafter."}],"balance_after":275000,"derivative":{"exercise_price":7.89,"expiration_date":"2030-10-11","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0001333277-20-000005","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000133327720000005/edgar.xml","form_type":"4"}},{"id":3681498,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-01-31T17:29:04.000Z","date":"2019-01-29","kind":"grant","acquired":true,"shares":86445,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/4 of the underlying shares on January 1, 2020, and vests as to 1/48 of the underlying shares monthly thereafter."}],"balance_after":86445,"derivative":{"exercise_price":8.43,"expiration_date":"2029-01-28","underlying":"Common Stock","underlying_shares":86445},"source":{"system":"sec-edgar","filing":"0001333277-19-000029","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000133327719000029/edgar.xml","form_type":"4"}},{"id":4088447,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-01-26T17:11:15.000Z","date":"2018-01-24","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 1/4 of the underlying shares on January 1, 2019, and vests as to 1/48 of the underlying shares monthly thereafter."}],"balance_after":50000,"derivative":{"exercise_price":11.69,"expiration_date":"2028-01-23","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001333277-18-000026","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000133327718000026/edgar.xml","form_type":"4"}},{"id":4088446,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-01-26T17:11:15.000Z","date":"2018-01-24","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/4 of the underlying shares on December 4, 2018, and vests as to 1/48 of the underlying shares monthly thereafter."}],"balance_after":250000,"derivative":{"exercise_price":11.69,"expiration_date":"2028-01-23","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001333277-18-000026","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000133327718000026/edgar.xml","form_type":"4"}},{"id":4388338,"issuer":{"id":175855,"kind":"organization","name":"TerraVia Holdings, Inc.","symbol":"TVIA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2017-03-13T16:58:36.000Z","date":"2017-03-09","kind":"sale","acquired":false,"shares":25000,"price":0.8093,"value":20232.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan in connection with the concurrent vesting of restrictred stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $0.7601 to $0.9045, inclusive.  The reporting person undertakes to provide to TerraVia Holdings, Inc., any security holder of TerraVia Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":218403,"source":{"system":"sec-edgar","filing":"0001555667-17-000007","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311230/000155566717000007/edgar.xml","form_type":"4"}},{"id":4461247,"issuer":{"id":175855,"kind":"organization","name":"TerraVia Holdings, Inc.","symbol":"TVIA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-02-08T18:55:07.000Z","date":"2017-02-06","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shall vest as to 1/48 of the underlying shares monthly beginning on February 1, 2017."}],"balance_after":200000,"derivative":{"exercise_price":0.86,"expiration_date":"2027-02-05","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001555667-17-000002","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1311230/000155566717000002/edgar.xml","form_type":"4"}},{"id":4461246,"issuer":{"id":175855,"kind":"organization","name":"TerraVia Holdings, Inc.","symbol":"TVIA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2017-02-08T18:55:07.000Z","date":"2017-02-06","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The grant shall vest as to all of the shares on March 5, 2018."}],"balance_after":243403,"source":{"system":"sec-edgar","filing":"0001555667-17-000002","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311230/000155566717000002/edgar.xml","form_type":"4"}},{"id":4461245,"issuer":{"id":175855,"kind":"organization","name":"TerraVia Holdings, Inc.","symbol":"TVIA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2017-02-08T18:55:07.000Z","date":"2017-02-06","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The grant shall vest as to 1/4 of the shares on March 5, 2018 and thereafter shall vest as to 1/8 of the shares on each of September 10, 2018, March 4, 2019, September 9, 2019, March 2, 2020, September 14, 2020 and March 1, 2021."}],"balance_after":220403,"source":{"system":"sec-edgar","filing":"0001555667-17-000002","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311230/000155566717000002/edgar.xml","form_type":"4"}},{"id":4579552,"issuer":{"id":175855,"kind":"organization","name":"TerraVia Holdings, Inc.","symbol":"TVIA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2016-10-14T17:38:54.000Z","date":"2016-10-14","kind":"sale","acquired":false,"shares":10000,"price":2.5528,"value":25528.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $2.525 to $2.58, inclusive.  The reporting person undertakes to provide to TerraVia Holdings, Inc., any security holder of TerraVia Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Corrects prior share ownership total that overstated holdings by 125 shares."}],"balance_after":120403,"source":{"system":"sec-edgar","filing":"0001555667-16-000092","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311230/000155566716000092/edgar.xml","form_type":"4"}},{"id":4601314,"issuer":{"id":175855,"kind":"organization","name":"TerraVia Holdings, Inc.","symbol":"TVIA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2016-09-16T16:11:02.000Z","date":"2016-09-16","kind":"sale","acquired":false,"shares":3124,"price":2.6016,"value":8127.3984,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was designed to cover tax withholding obligations in connection with the concurrent vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $2.59 to $2.63, inclusive.  The reporting person undertakes to provide to TerraVia Holdings, Inc., any security holder of TerraVia Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":130528,"source":{"system":"sec-edgar","filing":"0001555667-16-000091","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311230/000155566716000091/edgar.xml","form_type":"4"}},{"id":4602450,"issuer":{"id":175855,"kind":"organization","name":"TerraVia Holdings, Inc.","symbol":"TVIA"},"owners":[{"id":23524,"kind":"person","name":"Quinlan Paul T","position":1,"cik":"0001333277","reported_name":"Quinlan Paul T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2016-09-15T19:57:38.000Z","date":"2016-09-13","kind":"sale","acquired":false,"shares":1562,"price":2.7355,"value":4272.851,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was designed to cover tax withholding obligations in connection with the concurrent vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $2.69 to $2.77, inclusive.  The reporting person undertakes to provide to TerraVia Holdings, Inc., any security holder of TerraVia Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 2,207 shares acquired under the TerraVia Holdings, Inc. Employee Stock Purchase Plan on August 15, 2016."}],"balance_after":133652,"source":{"system":"sec-edgar","filing":"0001555667-16-000090","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311230/000155566716000090/edgar.xml","form_type":"4"}}]}